All In Biotech

Drug Trial Radar · NCT05262556

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Pilot Study of NP-101 (TQ Formula) in Combination With Nivolumab and Ipilimumab in Advanced and Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECAs)

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Dec 15, 2022

Primary completion

Oct 27, 2025

Study completion Oct 27, 2025

Sponsor

Lead sponsor
Amr Mohamed MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novatek Pharmaceuticals
First posted
Mar 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A pilot study to evaluate the anti-tumor efficacy of this novel combined regimen (NP-101 TQ Formula plus nivolumab and ipilimumab) in the second-line setting for EP-NECA. NP-101 (TQ Formula) (TQ, C10H12O2) is the main bioactive component of the black seed (Nigella sativa, Ranunculaceae family) and has anti-oxidant, anti-angiogenic effects.

Conditions

  • Gastroenteropancreatic Neuroendocrine Tumor
  • Gastroenteropancreatic Neuroendocrine Neoplasm
  • Neuroendocrine Carcinoma
  • Mixed Neuroendocrine-Non Neuroendocrine Neoplasm

Interventions

  • NP-101 (TQ Formula)Drug

    Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.

  • Nivolumab (3mg/kg)Drug

    Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.

  • Ipilimumab (1mg/kg)Drug

    Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Antitumor activity of NP-101 (TQ Formula) plus nivolumab and ipilimumab in subjects with advanced and/or metastatic EP-NECAs who progressed on first line therapyTime frame: Up to 6 months from the start of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

    Cleveland, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.